Literature DB >> 17485207

Paclitaxel C-10 carbamates: potential candidates for the treatment of neurodegenerative tauopathies.

Carlo Ballatore1, Edward Hyde, Robert F Deiches, Virginia M-Y Lee, John Q Trojanowski, Donna Huryn, Amos B Smith.   

Abstract

A series of paclitaxel C-10 carbamates was synthesized and evaluated in a bi-directional permeability assay in comparison with paclitaxel and the blood-brain barrier-permeable C-10 ester derivative, TX-67. A number of the carbamates were found not to be substrates for Pgp. Moreover, when tested for Pgp-inhibitory potential, representative compounds proved to be devoid of Pgp interactions. Side-by-side comparison between TX-67 and the corresponding C-10 carbamate, CNDR-3, revealed a significantly longer half-life for CNDR-3 in both mouse and human plasma, suggesting that this class of derivatives is appropriate for further in vivo evaluation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17485207      PMCID: PMC2648301          DOI: 10.1016/j.bmcl.2007.04.058

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  20 in total

1.  Micellar paclitaxel improves severe psoriasis in a prospective phase II pilot study.

Authors:  Alison Ehrlich; Susan Booher; Yvonne Becerra; Debra L Borris; W Douglas Figg; Maria L Turner; Andrew Blauvelt
Journal:  J Am Acad Dermatol       Date:  2004-04       Impact factor: 11.527

2.  Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo.

Authors:  Stephan Fellner; Björn Bauer; David S Miller; Martina Schaffrik; Martina Fankhänel; Thilo Spruss; Günther Bernhardt; Claudia Graeff; Lothar Färber; Harald Gschaidmeier; Armin Buschauer; Gert Fricker
Journal:  J Clin Invest       Date:  2002-11       Impact factor: 14.808

Review 3.  Microtubule stabilizing drugs for the treatment of Alzheimer's disease.

Authors:  V M Lee; R Daughenbaugh; J Q Trojanowski
Journal:  Neurobiol Aging       Date:  1994       Impact factor: 4.673

4.  Paclitaxel (Taxol) attenuates clinical disease in a spontaneously demyelinating transgenic mouse and induces remyelination.

Authors:  M A Moscarello; B Mak; T A Nguyen; D D Wood; F Mastronardi; S K Ludwin
Journal:  Mult Scler       Date:  2002-04       Impact factor: 6.312

5.  Effects of paclitaxel on cultured synovial cells from patients with rheumatoid arthritis.

Authors:  A Kurose; W Yoshida; M Yoshida; T Sawai
Journal:  Cytometry       Date:  2001-08-01

6.  Syntheses and structure-activity relationships of the second-generation antitumor taxoids: exceptional activity against drug-resistant cancer cells.

Authors:  I Ojima; J C Slater; E Michaud; S D Kuduk; P Y Bounaud; P Vrignaud; M C Bissery; J M Veith; P Pera; R J Bernacki
Journal:  J Med Chem       Date:  1996-09-27       Impact factor: 7.446

7.  Broad-spectrum modulation of ATP-binding cassette transport proteins by the taxane derivatives ortataxel (IDN-5109, BAY 59-8862) and tRA96023.

Authors:  Hans Minderman; Tracy A Brooks; Kieran L O'Loughlin; Iwao Ojima; Ralph J Bernacki; Maria R Baer
Journal:  Cancer Chemother Pharmacol       Date:  2004-01-27       Impact factor: 3.333

8.  DJ-927, a novel oral taxane, overcomes P-glycoprotein-mediated multidrug resistance in vitro and in vivo.

Authors:  Motoko Shionoya; Takeshi Jimbo; Mayumi Kitagawa; Tsunehiko Soga; Akiko Tohgo
Journal:  Cancer Sci       Date:  2003-05       Impact factor: 6.716

Review 9.  Paclitaxel (taxol)

Authors:  E K Rowinsky; R C Donehower
Journal:  N Engl J Med       Date:  1995-04-13       Impact factor: 91.245

10.  Antitumour activity of novel taxanes that act at the same time as cytotoxic agents and P-glycoprotein inhibitors.

Authors:  C Ferlini; M Distefano; F Pignatelli; S Lin; A Riva; E Bombardelli; S Mancuso; I Ojima; G Scambia
Journal:  Br J Cancer       Date:  2000-12       Impact factor: 7.640

View more
  10 in total

Review 1.  Novel therapeutics for Alzheimer's disease: an update.

Authors:  David J Bonda; Hyun-Pil Lee; Hyoung-gon Lee; Avi L Friedlich; George Perry; Xiongwei Zhu; Mark A Smith
Journal:  Curr Opin Drug Discov Devel       Date:  2010-03

Review 2.  Brain-penetrant microtubule-stabilizing compounds as potential therapeutic agents for tauopathies.

Authors:  Kurt R Brunden; Carlo Ballatore; Virginia M-Y Lee; Amos B Smith; John Q Trojanowski
Journal:  Biochem Soc Trans       Date:  2012-08       Impact factor: 5.407

3.  The characterization of microtubule-stabilizing drugs as possible therapeutic agents for Alzheimer's disease and related tauopathies.

Authors:  Kurt R Brunden; Yuemang Yao; Justin S Potuzak; Nuria Ibarz Ferrer; Carlo Ballatore; Michael J James; Anne-Marie L Hogan; John Q Trojanowski; Amos B Smith; Virginia M-Y Lee
Journal:  Pharmacol Res       Date:  2010-12-14       Impact factor: 7.658

Review 4.  Developing therapeutic approaches to tau, selected kinases, and related neuronal protein targets.

Authors:  Virginia M-Y Lee; Kurt R Brunden; Michael Hutton; John Q Trojanowski
Journal:  Cold Spring Harb Perspect Med       Date:  2011-09       Impact factor: 6.915

Review 5.  Modulation of protein-protein interactions as a therapeutic strategy for the treatment of neurodegenerative tauopathies.

Authors:  C Ballatore; K R Brunden; J Q Trojanowski; V M-Y Lee; A B Smith; D M Huryn
Journal:  Curr Top Med Chem       Date:  2011       Impact factor: 3.295

6.  In situ blood-brain barrier permeability of a C-10 paclitaxel carbamate.

Authors:  Carlo Ballatore; Bin Zhang; John Q Trojanowski; Virginia M-Y Lee; Amos B Smith
Journal:  Bioorg Med Chem Lett       Date:  2008-10-10       Impact factor: 2.823

7.  Cyclic AMP-dependent protein kinase enhances SC35-promoted Tau exon 10 inclusion.

Authors:  Caoyi Chen; Nana Jin; Wei Qian; Wen Liu; Xiangling Tan; Fei Ding; Xiaosong Gu; Khalid Iqbal; Cheng-Xin Gong; Ji Zuo; Fei Liu
Journal:  Mol Neurobiol       Date:  2013-09-14       Impact factor: 5.590

Review 8.  Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies.

Authors:  Kurt R Brunden; John Q Trojanowski; Virginia M-Y Lee
Journal:  Nat Rev Drug Discov       Date:  2009-10       Impact factor: 84.694

9.  Up-regulation of casein kinase 1ε is involved in tau pathogenesis in Alzheimer's disease.

Authors:  Caoyi Chen; Jianlan Gu; Gustavo Basurto-Islas; Nana Jin; Feng Wu; Cheng-Xin Gong; Khalid Iqbal; Fei Liu
Journal:  Sci Rep       Date:  2017-10-18       Impact factor: 4.379

10.  Modulation of blood-brain barrier permeability in mice using synthetic E-cadherin peptide.

Authors:  Ngoc H On; Paul Kiptoo; Teruna J Siahaan; Donald W Miller
Journal:  Mol Pharm       Date:  2014-02-19       Impact factor: 4.939

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.